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Over the past twenty years, opioid use during pregnancy has become much more
common (Haight et al., 2018). Opioids may be prescribed for pain management or the
treatment of an opioid use disorder (OUD). For example, methadone or buprenorphine
are medications recommended for pregnant women with OUD. Opioid use may also
include misusing prescription painkillers or using illicit drugs such as heroin. Regardless
of the nature of opioid use, it is important for pregnant women to know how opioid use
can impact their pregnancy and what treatment options are available.

Basic Facts

● Drug overdose is the number one cause of death in Utah for women who recently delivered a
baby, and 77% of these deaths are due to opioids (Smid et al., 2019).
● While babies cannot be “addicted” to opioids because they lack the social factors necessary for
an addiction diagnosis, babies exposed to opioids in utero, especially illicit opioids like heroin,
have higher risks of poor growth, premature birth, and opioid withdrawal symptoms (Centers
for Disease Control [CDC], 2021; Reddy et al., 2017).
● Prenatal care and checking a baby’s health after birth is especially important for parents who
use opioids (American College of Obstetrics and Gynecology, 2017; CDC, 2021; Reddy et al.,
2017).
● Effective medical treatments for OUD, such as methadone and buprenorphine, can help women have a healthy pregnancy and reduce the risk of health problems for babies compared to
babies born to women with untreated OUD (Brogly et al., 2014; CDC, 2021; Jones et al.,
2010; Reddy et al., 2017).

Trends

● Between 1999 and 2014, OUD in pregnancy rose at an alarming rate, up over 333% in the
United States (1.5 to 6.5 per 1,000 delivery ospitalizations). In Utah, the rate of increase was
even greater, up 825% (0.4 to 3.7 per 1,000 delivery hospitalizations) (Haight et al., 2018).
● In a nine-year period between 2005 and 2014, 27 women died of opioid overdose in Utah
within a year of giving birth (Smid et al., 2019).
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Healthy Outcomes
● With proper medications for opioid use disorder (MOUD) treatment for women during
pregnancy, babies are at lower risk of being born too early, too small, or having opioid
withdrawal after birth when exposed to opioids during pregnancy (CDC, 2019).
● Mothers who received MOUD were more likely to track their baby’s growth and health
appropriately and maintain custody than mothers with untreated OUD (Berg et al.,
2008).
● Mothers receiving MOUD during pregnancy are more likely to have a baby with a healthy
birth weight and less likely to deliver their baby prematurely (Berg et al., 2008).
● Establishing and implementing a plan can lead to healthier outcomes for mothers and
infants (Figure 1).

Figure 1. Map for Healthy Outcomes for Mother and Baby
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Treatment Resources
Call the Substance Abuse and Mental Health Services Administration (SAMHSA)
National Helpline: 1-800-662-HELP (4357) – free and confidential, 24/7 treatment
referral and information, available in English and Spanish.

Find a provider near you using the SAMHSA Opioid Treatment Program Directory:
OTP Directory (samhsa.gov).

Access Pregnancy Resources for Women and Families from the Utah Department
of Health, Maternal and Infant Health Program: https://mihp.utah.gov/opioids.

Use Resources on Opioid Use During
Pregnancy from the Centers for Disease Control and Prevention: https://www.cdc.gov/
pregnancy/ opioids/resources.html.

Local Resources
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